FibroGen Inc (FGEN)
0.9041
-0.13
(-12.22%)
USD |
NASDAQ |
Jun 28, 16:00
0.9111
+0.01
(+0.77%)
After-Hours: 20:00
FibroGen Research and Development Expense (TTM): 246.77M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 246.77M |
| December 31, 2023 | 282.86M |
| September 30, 2023 | 292.79M |
| June 30, 2023 | 306.77M |
| March 31, 2023 | 282.26M |
| December 31, 2022 | 296.79M |
| September 30, 2022 | 349.08M |
| June 30, 2022 | 349.78M |
| March 31, 2022 | 401.38M |
| December 31, 2021 | 387.04M |
| September 30, 2021 | 351.26M |
| June 30, 2021 | 333.85M |
| March 31, 2021 | 272.70M |
| December 31, 2020 | 252.92M |
| September 30, 2020 | 231.59M |
| June 30, 2020 | 223.08M |
| March 31, 2020 | 213.67M |
| December 31, 2019 | 209.26M |
| September 30, 2019 | 222.75M |
| June 30, 2019 | 229.23M |
| Date | Value |
|---|---|
| March 31, 2019 | 229.36M |
| December 31, 2018 | 235.84M |
| September 30, 2018 | 218.02M |
| June 30, 2018 | 211.92M |
| March 31, 2018 | 206.76M |
| December 31, 2017 | 196.52M |
| September 30, 2017 | 194.66M |
| June 30, 2017 | 184.88M |
| March 31, 2017 | 190.29M |
| December 31, 2016 | 187.21M |
| September 30, 2016 | 196.52M |
| June 30, 2016 | 208.04M |
| March 31, 2016 | 207.20M |
| December 31, 2015 | 214.09M |
| September 30, 2015 | 205.42M |
| June 30, 2015 | 193.97M |
| March 31, 2015 | 175.68M |
| December 31, 2014 | 150.79M |
| September 30, 2014 | 128.97M |
| June 30, 2014 | 111.54M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
209.26M
Minimum
Dec 2019
401.38M
Maximum
Mar 2022
286.79M
Average
282.56M
Median
Research and Development Expense (TTM) Benchmarks
| Regeneron Pharmaceuticals Inc | 4.586B |
| Annovis Bio Inc | 37.52M |
| Vertex Pharmaceuticals Inc | 3.209B |
| Enanta Pharmaceuticals Inc | 151.11M |
| Nanoviricides Inc | 7.168M |